Healthcare >> CEO Interviews >> September 13, 2002
ROLF STAHEL is the Chief Executive of Shire Pharmaceuticals Group Plc.
He is a Swiss national, a graduate in Business Studies and attended the
97th Advanced Management Program (AMP) at Harvard. He worked for 27
years with Wellcome plc in Switzerland, Italy, Thailand, Singapore and
the UK. As Regional Director, based in Singapore, Mr. Stahel was
responsible for 18 Pacific Rim countries. His last position with
Wellcome was Director of Group Marketing, based in London and Beckenham,
covering Group Strategy, R&D portfolio evaluation, marketing of existing
and new products and business development. In this position, Mr. Stahel
reported to the Chief Executive of Wellcome. Mr. Stahel joined Shire
Pharmaceuticals Group Plc in March 1994 as its Chief Executive. On March
15, 2001, Mr. Stahel received the Chief Executive Officer of the Year
Award 2001 for the global pharmaceutical industry. Mr. Stahel is a Main
Board Director of Shire and is also Chairman of the Executive Committee. Profile
you see the company today?
Mr. Stahel: First, Shire is a global pharmaceutical company that is
targeting specialty
